President & COO, Ajinomoto Bio-Pharma Services United States
Bert Barbosa joined the leadership team in May 2018, bringing with him over 35 years of bio-pharmaceutical production, quality assurance and compliance leadership and management experience. As President & COO of Ajinomoto Bio-Pharma Services United States, he is responsible for overseeing all aspects of the CDMO business at the US site.
Mr. Barbosa previously worked at Allergan, where he most recently served as Director QA/QC, Drug Substance Operations, responsible for quality and compliance oversight of commercial and investigational drug substance at two facilities. Prior to Allergan, Mr. Barbosa was at Amylin Pharmaceuticals in the positions of Director, Development Quality and Director, Quality Manufacturing. There his duties included overseeing quality and commercial manufacturing activities for global distribution.
At Chiron Corporation (Novartis), Mr. Barbosa has also held the positions of Director of Parental Operations and Director of Quality, where he was responsible for sterile parenteral filling and finishing operations, and commercial QA product release activities. He gained considerable quality experience through progressing quality leadership positions at Vical, Inc. and Hybritech, Inc., bio-pharmaceutical manufacturers located in San Diego.
Joining Ajinomoto Bio-Pharma Services in 2018 as VP of Drug Product, he was responsible for overseeing and managing the drug product manufacturing operations, ADC/Cytotoxic product development activities and associated personnel. He then moved into the role of Sr. VP of Corporate Strategy in 2021, followed by the Executive VP of Operations position in 2022.
Mr. Barbosa holds a BS in Biochemistry from San Francisco State University.